Memorial Sloan Kettering Cancer Center

Syndax Pharmaceuticals announced positive Phase 2 trial results for revumenib in treating relapsed or refractory mutant NPM1 acute myeloid leukemia, with a 23% complete remission rate and a 47% overall response rate in heavily pre-treated patients. The company plans to file a supplemental New Drug Application in 2025 and present further data at the American Society of Hematology Annual Meeting in December 2024.

Revumenib (SNDX-5613), an oral Menin inhibitor, achieved a 23% complete remission (CR) or CR with partial blood count recovery rate (CRh) in efficacy-evaluable adult patients with relapsed/refractory (R/R) NPM1-mutant (mNPM1) acute myeloid leukemia (AML) in the phase 2 AUGMENT-101 trial. The median duration of response was 4.7 months, with 64% of CR/CRh patients becoming minimal residual disease (MRD)-negative. The overall response rate (ORR) was 47%, and revumenib's safety profile aligned with prior data, with treatment-related adverse events (TRAEs) leading to discontinuation in 5% of patients.

Syndax announces positive Phase 2 AUGMENT-101 trial results for revumenib in relapsed or refractory mutant NPM1 acute myeloid leukemia (AML), achieving a 23% complete remission rate. The drug, an oral menin inhibitor, shows promise in heavily pretreated patients, with 47% overall response rate and 64% minimal residual disease negativity. Upcoming milestones include FDA approval for R/R KMT2A-rearranged acute leukemias, data presentation at ASH 2024, and initiation of a pivotal combination trial.

Gastric cancer affects 26,890 people annually in the US, with 10,880 expected deaths in 2024. Risk factors include smoking, age, diet, and stomach inflammation. Cell therapy, particularly CAR-T, is a focus for new treatments. CARsgen completed patient enrollment for its CLDN18.2-targeting CAR-T therapy satri-cel in China. The first patient with refractory gastroesophageal cancer was dosed in a phase 2 trial combining iNKT cell therapy agenT-797 with immune checkpoint inhibitors. Triumvira’s TAC01-CLDN18.2 is set for a phase 1/2 trial for solid tumors. Biosyngen’s TCR-T therapy BRL03 received FDA clearance for trials in lung and gastric cancers.

Y-mAbs Therapeutics reported Q3 2024 net revenue of $18.5 million, a 10% decrease from Q3 2023, attributed to reduced product revenues and prior licensing revenue. Despite this, net revenue for the first nine months of 2024 remained stable at $61.2 million. The FDA-approved therapy DANYELZA saw a 5% drop in U.S. product revenues, influenced by Medicaid claim adjustments and increased competition. Y-mAbs maintained its full-year revenue guidance of $87-95 million, expecting to fall in the lower half of the range, and emphasized its strategic focus on drug development, including advancements in its SADA PRIT technology platform and a new licensing agreement for potential commercialization in Japan.

ALLO-316, a CD70-targeted CAR T-cell therapy, demonstrated durable activity in advanced kidney cancer patients, with 25% of CD70 TPS ≥50 patients responding, rising to 40% with FC lymphodepletion. Higher dose treatment showed responses in half of patients. Safety profile was manageable, with a focus on reducing immune effector cell-related syndromes. The TRAVERSE trial supports further evaluation in CD70-positive RCC and other malignancies.

Palmetto GBA expands Medicare coverage of clonoSEQ for measurable residual disease (MRD) detection and monitoring in mantle cell lymphoma (MCL) patients, enhancing treatment response assessment and relapse prediction.

Combination therapy with enfortumab vedotin and pembrolizumab showed durable responses and meaningful survival in cisplatin-ineligible patients with urothelial cancer, with 47% still in remission at 5 years and 41.5% overall survival.

Dr. Selwyn M. Vickers received the 2024 Cato T. Laurencin Lifetime Research Award at the National Medical Association’s Annual Convention. The award, presented by Laurencin, recognizes Vickers' over 20 years of contributions to human health and cancer research, particularly in pancreatic and gastrointestinal cancers.

Becker's 2024 list highlights hospitals & health systems excelling in oncology, recognized for advanced clinical trials & research. Notable institutions include AdventHealth, Allina Health, Arkansas Children's, Atlantic Health System, Banner MD Anderson Cancer Center, Baylor Scott & White Health, Boston Medical Center, Brown University Health, Children's Health, Children's Hospital Colorado, Children’s Hospital Los Angeles, Children’s Hospital of Orange County, Children's Hospital of Philadelphia, Children's Nebraska, ChristianaCare, City of Hope Comprehensive Cancer Center, Cleveland Clinic, Connecticut Children’s, Covenant Health, Dana-Farber Cancer Institute, Dartmouth Health, DeTar Hospital Cancer Center, Duke Health, El Paso Children's Hospital, Emory Healthcare, Endeavor Health, Fred Hutchinson Cancer Center/UW Medicine, Geisinger, Hackensack Meridian Health, Huntsman Cancer Institute at the University of Utah, Inova, Jefferson Health, Johns Hopkins, Jupiter Medical Center, Keck Medicine of USC, Laredo Medical Center, Lehigh Valley Health Network, MUSC Health, MaineHealth, Massachusetts General Hospital, Mayo Clinic, MedStar, MemorialCare, Memorial Sloan Kettering Cancer Center, Michigan Medicine, Mount Sinai Health System, Nebraska Medicine, New York-Presbyterian Hospital-Columbia and Cornell, Northwestern Medicine, Novant Health, OSF HealthCare, OU Health, Ochsner Health, Ohio State University Comprehensive Cancer Center, Oregon Health & Science University Hospital, Orlando Health, Penn Medicine, Providence Alaska Medical Center, Providence Cancer Institute of Oregon, Providence South Division Cancer Institute, Queen's Health System, RWJBarnabas Health and Rutgers Cancer Institute, Renown Health, Rochester Regional Health, Roper St. Francis Healthcare, Roswell Park Comprehensive Cancer Center, Sanford Health, Sarasota Memorial Health Care System, Scripps Health, St. Jude Children's Research Hospital, Stanford Medicine, Stanford Medicine Children's Health, Sutter Health, Swedish Cancer Institute, Sylvester Comprehensive Cancer Center at University of Miami, Tampa General Hospital, Texas Children's Hospital, UC Davis Health, UCLA Health, UCSF Health, UK HealthCare, UNM Health System, UVA Health, UW Health, UMass Memorial Health, University of Alabama Birmingham Hospital, University of Chicago Medical Center, University of Colorado Cancer Center-UCHealth University of Colorado Hospital, University Hospitals, University of Iowa Health Care, University of Kansas Health System, University of Texas MD Anderson Cancer Center, University of Vermont Health Network, Vanderbilt University Medical Center, Virtua Health, WVU Cancer Institute, WellSpan Health, Yale New Haven Health.